Drug Profile
APD 597
Alternative Names: APD597; JNJ-38431055Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Suspended Type 2 diabetes mellitus
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 09 Nov 2010 Ortho-McNeil-Janssen Pharmaceuticals announces termination of collaboration with Arena Pharmaceuticals
- 09 Nov 2010 Safety and pharmacokinetics data from a phase I clinical programme released by Arena Pharmaceuticals